Broad Pipeline of Internally Discovered Agents

Lead asset in pivotal trials both globally and in China, additional pivotal programs to start in 2017.

pipline

In total, over 980 patients and healthy adults2 enrolled 4 programs including combination trials

  • All 4 compounds in clinic both globally and in China
  • Lead compound in pivotal trials both globally and in China

1 Limited collaboration with Merck KGaA;

2As of November 7, 2016

jietu20170326-184738

  • All 4 compounds in clinic in China
  • Lead compound in pivotal trials in China

Combinations in Development

Broad internal portfolio provides advantages in combination therapy.

jietu20170326-184841